Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:03 pm Sale | 2025-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Citadel Advisors LLC | 1,988,907 3.400% | -1,020,219 (-33.90%) | Filing History |
| 2025-11-14 2:00 pm Sale | 2025-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 5,766,090 9.800% | -2,782,994 (-32.55%) | Filing History |
| 2025-11-13 4:28 pm Sale | 2025-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Deerfield Mgmt, L.P. | 2,927,013 4.950% | -356,811 (-10.87%) | Filing History |
| 2025-10-30 2:57 pm Sale | 2025-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | The Vanguard Group | 2,943,325 4.980% | -55,389 (-1.85%) | Filing History |
| 2025-10-10 6:53 pm Purchase | 2025-10-08 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 8,549,084 14.500% | 4,148,242 (+94.26%) | Filing History |
| 2025-08-14 06:58 am Purchase | 2025-06-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 4,400,842 7.500% | 4,400,842 (New Position) | Filing History |
| 2025-08-06 6:55 pm Purchase | 2025-07-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Citadel Advisors LLC | 3,009,126 5.100% | 3,009,126 (New Position) | Filing History |
| 2024-11-14 5:05 pm Sale | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Blue Owl Capital Holdings LP | 2,010,972 3.450% | -1,408,870 (-41.20%) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 5,796,433 9.990% | 1,403,112 (+31.94%) | Filing History |
| 2024-11-12 2:23 pm Unchanged | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | The Vanguard Group | 2,998,714 5.170% | 0 (Unchanged) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | BlackRock Inc. BLK | 4,338,725 7.500% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:18 am Purchase | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | The Vanguard Group | 2,998,714 5.170% | 1,227,271 (+69.28%) | Filing History |
| 2024-10-31 12:48 pm Sale | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | FRANKLIN RESOURCES INC BEN | 2,191,262 3.800% | -1,090,018 (-33.22%) | Filing History |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | BlackRock Inc. BLK | 4,338,725 7.500% | 1,589,995 (+57.84%) | Filing History |
| 2024-06-07 1:30 pm Purchase | 2024-05-31 | 13G | Cullinan Therapeutics, Inc. CGEM | BlackRock Inc. BLK | 2,748,730 4.800% | 286,456 (+11.63%) | Filing History |
| 2024-04-24 5:50 pm Purchase | 2024-04-18 | 13G | Cullinan Therapeutics, Inc. CGEM | Deerfield Mgmt, L.P. | 3,283,824 5.710% | 3,283,824 (New Position) | Filing History |
| 2024-02-14 9:01 pm Purchase | 2023-12-31 | 13G | Cullinan Therapeutics, Inc. CGEM | Blue Owl Capital Holdings LP | 3,419,842 7.990% | 3,419,842 (New Position) | Filing History |
| 2024-02-14 4:59 pm Sale | 2023-12-31 | 13G | Cullinan Therapeutics, Inc. CGEM | Jovan-Embiricos Morana | 2,177,461 5.090% | -1,606,510 (-42.46%) | Filing History |
| 2024-02-14 10:16 am Sale | 2023-12-31 | 13G | Cullinan Therapeutics, Inc. CGEM | BIOTECHNOLOGY VALUE FUND L P | 4,393,321 9.990% | -3,115,738 (-41.49%) | Filing History |
| 2024-02-13 5:02 pm Sale | 2023-12-29 | 13G | Cullinan Therapeutics, Inc. CGEM | The Vanguard Group | 1,771,443 4.140% | -1,041,522 (-37.03%) | Filing History |